Get started
Author

Pranay D. Khare

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
2015 · Steven C. Katz, Rachel A. Burga, et al. · Clinical Cancer Research · 397
Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma
2016 · Marshall E. Kadin, Anand Deva, et al. · Aesthetic Surgery Journal · 157
Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma
2018 · John A. Barrett, Hongliang Cai, et al. · Cancer Gene Therapy · 101
PDF
Specifically targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase.
2001 · P D Khare, L Shao-Xi, et al. · PubMed · 57
Durable, Safe, Multi-gene Lentiviral Vector Expression in Feline Trabecular Meshwork
2007 · Pranay D Khare, Nils Loewen, et al. · Molecular Therapy · 50
Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases
2014 · A Saied, L Licata, et al. · Cancer Gene Therapy · 39
Tumor growth suppression by a retroviral vector displaying scFv antibody to CEA and carrying the iNOS gene.
2002 · Pranay D Khare, Shaoxi Liao, et al. · PubMed · 23
Epitope selection from an uncensored peptide library displayed on avian leukosis virus
2003 · Pranay D Khare, Ana G Rosales, et al. · Virology · 18
PDF
Avian leukosis virus is a versatile eukaryotic platform for polypeptide display
2003 · Pranay D Khare, Stephen J Russell, et al. · Virology · 17
Soluble Thrombospondin-1 Suppresses T Cell Proliferation and Enhances Il-10 Secretion by Antigen Presenting Cells Stimulated With Phytohemagglutinin
2001 · Richiko Beppu, Ken Nakamura, et al. · Immunological Investigations · 14
CD19-Specific Chimeric Antigen Receptor-Modified T Cells with Safety Switch Produced Under “Point-of-Care” Using the Sleeping Beauty System for the Very Rapid Manufacture and Treatment of B-Cell Malignancies
2017 · Tim Hon Man Chan, John T. Gallagher, et al. · Blood · 5
Growth arrest and apoptosis in adult T cell leukemia cell lines following IL-2 deprivation
2004 · Satoshi Fujimura, Fumiko Arakawa, et al. · International Journal of Oncology · 4
Identification and characterization of receptor for dengue virus-induced macrophage cytotoxin.
1996 · P D Khare, R Dhawan, et al. · PubMed · 4
PS3-58 Comprehensive Borrelia burgdorferi specific inflammatory immune response analysis in patients with Lyme disease
2010 · Pranay D. Khare, Meenakshi Khare, et al. · Cytokine · 1
375. A Glaucoma Gene Therapy Model: Eighteen Cat Study Revealing Long-Term Targeted Genetic Modification of the Anterior Chamber by Lentiviral Vectors
2006 · Pranay D. Khare, Nils Loewen, et al. · Molecular Therapy · 1
Identification, purification and characterization of a receptor for dengue virus-induced macrophage cytotoxin (CF2) from murine T cells
2003 · Pranay Deep Khare, Meenakshi Khare, et al. · FEMS Immunology & Medical Microbiology · 1
PDF
Supplemental Figure 1 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
2023 · Steven C. Katz, Rachel A. Burga, et al.
Supplemental Figure 3 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
2023 · Steven C. Katz, Rachel A. Burga, et al.
Supplemental Figure 2 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
2023 · Steven C. Katz, Rachel A. Burga, et al.
Supplemental Figure 4 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
2023 · Steven C. Katz, Rachel A. Burga, et al.
Data from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
2023 · Steven C. Katz, Rachel A. Burga, et al.
Data from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
2023 · Steven C. Katz, Rachel A. Burga, et al.
Supplemental Figure 3 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
2023 · Steven C. Katz, Rachel A. Burga, et al.
Supplemental Figure 4 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
2023 · Steven C. Katz, Rachel A. Burga, et al.
Supplemental Figure 1 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
2023 · Steven C. Katz, Rachel A. Burga, et al.
Works count: 33
Citation count: 889
H-index: 10
I10-index: 10
Year
Topic
Type